Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as C$12.11 and last traded at C$12.11, with a volume of 166 shares traded. The stock had previously closed at C$11.79.
Fennec Pharmaceuticals Stock Performance
The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The firm's 50-day moving average is C$9.06 and its two-hundred day moving average is C$9.03. The stock has a market cap of C$218.69 million, a price-to-earnings ratio of -192.10 and a beta of 0.25.
Insider Activity at Fennec Pharmaceuticals
In related news, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of C$7.46, for a total value of C$74,550.00. Also, Senior Officer Robert Christopher Andrade purchased 8,220 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were purchased at an average price of C$6.99 per share, for a total transaction of C$57,433.14. In the last quarter, insiders sold 38,076 shares of company stock valued at $349,104. Corporate insiders own 16.20% of the company's stock.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
